Karli Rosner, MD, PhD

Karli Rosner, MD, PhD
Assistant Professor of Dermatology and of Molecular Medicne and Genetics
Director of Dermatologic Research, Department of Dermatology
Scott Hall, Rm 3224
540 E. Canfield Avenue
Detroit, MI 48201


PhD, University of Copenhagen 2001
MD, Faculty of Medicine, Ben-Gurion University 1988

Research Focus

Basic and translational sciences in skin cancer with emphasis on malignant melanoma and cutaneous lymphoma. Specifically addressing topics such as Melanoma Gene Therapy by Targeted Gene Constructs, Diagnostic Biomarkers of Melanoma by High-Throughput Antigen Cloning and Detection on Arrays, and The Role of Mobile Genetic Elements in the Etiology of Melanoma.

Select Publications

Rosner K, Kirou E, Mehregan DR, Abrams J, Kim S, Rosner T. Eradication of Multiple Primary and Metastatic Melanoma Types In Vitro by Human Recombinant DNase1. J Expt Derm Clin Res 1:004, 2014. Cited: x 0.

Rosner K, Adsule S, Haynes B, Kirou E, Kato I, Mehregan DR, Shekhar MPV. Rad6 is a Potential Early Marker of Melanoma Development. Submitted, Translational Oncology 2014, May 12. pii: S1936-5233(14)00044-8. [Epub ahead of print]. PMID: 24831578. IF:2.943. Cited: x 0.

Rosner K, Mehregan DR, Kirou E, Abrams J, Kim S, Campbell M, Frieder J, Lawrence K, Haynes B, Shekhar MPV. Melanoma Development and Progression are Associated with Rad6 Upregulation and β-catenin Relocation to the Cell Membrane. Submitted, J Skin Cancer 439205, 2014, 2014. PMID: 24891954. Cited: x 1.

Rosner K, Kasprzak MF, Horenstein ACJ, Thurston HL, Abrams J, Kerwin LY, Mehregan DA, Mehregan DR. Engineering a Waste Management Enzyme to Overcome Cancer Resistance to Apoptosis: Adding DNase1 to the Anti-Cancer Toolbox. Cancer Gene Ther 18: 346-57, 2011. PMID: 21233855. IF: 2.945. Cited: x 5.

Rosner K, Mehregan DR, Moussai D, Abrams J, Tromp G, Mehregan DA. WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi. J Cutan Pathol 36: 1077-82, 2009. PMID: 19615003. IF: 1.766. Cited: x 4.